Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices

Abstract

Vaccines represent one of the greatest achievements of science and medicine in the fight against infectious diseases. Vaccination is one of the most cost-effective public health tools to prevent infectious diseases. Significant progress has been made in expanding the coverage of vaccines globally, resulting in the prevention of more than two million deaths annually. In 2010, nearly 200 countries endorsed a shared vision to extend the benefits of vaccines to every person by 2020, known as the Decade of Vaccine Initiative (DoV). Vaccine manufacturers in developing countries, as represented by the Developing Countries Vaccine Manufacturers Network (DCVMN), make a significant contribution to DoV by supplying quality vaccines at affordable prices to the people who need them most. About 70% of the global Expanded Program on Immunization (EPI) vaccine supplies are met by DCVMN. Besides EPI vaccine supplies, DCVMN is also targeting vaccines against rotavirus, Japanese encephalitis, pneumonia, human papillomavirus, meningitis and neglected tropical diseases. This article reviews the roles and contributions of DCVMN in making the vaccines accessible and affordable to all.

Clinical Trial of Measles and Rubella Combined Vaccine Produced by POLYVAC in Vietnam

“…A stable supply at an affordable cost would increase vaccine coverage and contribute to measles and rubella eradication. Most vaccines in developed countries are produced in the U.S. and E.U., but recently vaccine manufacturers in developing countries began to supply the EPI vaccines [25]. The domestic capacity for vaccine production can cope with unexpected outbreaks.…”

CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

“…According to the WHO, an increased risk of hospitalized dengue was identified in the age group of 2 to 5 years old in the third year of follow up post dose 1. This fact, along with the lower efficacy observed in under 9 years-olds, led to a decision to exclude individuals aged 2-5 (and also those aged [62,63]. Specifically for dengue vaccine, it was estimated there would be 250 million dengue vaccines doses for Brazil and Colombia for the period 2015-2019, 38 million for routine doses, 148 million for catchup vaccination of under 15 year olds, and 62 million doses for vaccination of adults.…”

Highlights of the final draft of the national policy document for science, technology and innovation in vaccine production in Iran

“…Furthermore, for recent and future vaccines, the intellectual property would be a barrier to the technology transfer which would become a greater problem after 2016 deadline for enforcing pharmaceutical patents in WTO member countries comes into effect [10]. It has been estimated that the global vaccine market will be around US$ 84.44 billion by 2022 from around US$ 32.05 billion in 2012, resulting from the introduction of new products and rise in the demands [13]. Presently, the market is dominated by the developed world and the share of the developing countries is estimated at around 20%; however, it is anticipated that the collective share of India, China, Brazil, the Russian Federation, Republic of Korea, and Turkey (all members of the DCVMN) to become larger than the developed markets by 2020 [13].…”

“…It has been estimated that the global vaccine market will be around US$ 84.44 billion by 2022 from around US$ 32.05 billion in 2012, resulting from the introduction of new products and rise in the demands [13]. Presently, the market is dominated by the developed world and the share of the developing countries is estimated at around 20%; however, it is anticipated that the collective share of India, China, Brazil, the Russian Federation, Republic of Korea, and Turkey (all members of the DCVMN) to become larger than the developed markets by 2020 [13]. In view of the changes in the global vaccine market, it is imperative that the vaccine industry in Iran should change since remaining a supplier of traditional vaccines to the domestic market in the face of increasing competition from the emerging manufacturers is not a viable option [14].…”